Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer

Cancer

Volumn 117, Issue 3, 2011, Pages 480-491

  Dong, Xiaoqun ^a   Tang, Hongwei ^a   Hess, Kenneth R ^a   Abbruzzese, James L ^a   Li, Donghui ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

glucose metabolism; haplotype; overall survival; pancreatic adenocarcinoma; single nucleotide polymorphism

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GLUCOKINASE GENE; GLUCOSE METABOLISM; GLUCOSE PHOSPHATE ISOMERASE GENE; GLUTAMINE FRUCTOSE 6 PHOSPHATE TRANSAMINASE GENE; HAPLOTYPE; HEXOKINASE 2 GENE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; O LINKED N ACETYLGLUCOSAMINE TRANSFERASE GENE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENOTYPE; GLUCOSE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 79251517097     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25612     Document Type: Article

References (30)

1. Warburg O., On the origin of cancer cells. Science. 1956; 123: 309-314.
2. Vousden KH, Ryan KM., p53 and metabolism. Nat Rev Cancer. 2009; 9: 691-700.
3. Gatenby RA, Gillies RJ., Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 4: 891-899.
4. Gambhir SS., Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2: 683-693.
5. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med. 2002; 43: 173-180.
6. Natsuizaka M, Ozasa M, Darmanin S, et al. Synergistic up-regulation of hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res. 2007; 313: 3337-3348.
7. Peng SY, Lai PL, Pan HW, et al. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis. Oncol Rep. 2008; 19: 1045-1053.
8. Sperti C, Pasquali C, Chierichetti F, et al. 18-Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma. J Gastrointest Surg. 2003; 7: 953-959; discussion 959-960.
9. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
10. Hammerman PS, Fox CJ, Thompson CB., Beginnings of a signal-transduction pathway for bioenergetic control of cell survival. Trends Biochem Sci. 2004; 29: 586-592.
11. Cao X, Bloomston M, Zhang T, et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res. 2008; 14: 1831-1839.
12. Kurtoglu M, Maher JC, Lampidis TJ., Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal. 2007; 9: 1383-1390.
13. Hulleman E, Kazemier KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood. 2009; 113: 2014-2021.
14. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009; 301: 2553-2562.
15. Li D, Hassan MM, Abbruzzese JL., Obesity and survival among patients with pancreatic cancerâreply. JAMA. 2009; 302: 1752-1753.
16. Dong X, Jiao L, Li Y, et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol. 2009; 27: 1592-1599.
17. Dong X, Javle M, Hess KR, et al. Insulin-like growth factor axis gene polymorphisms and clinical outcome in pancreatic cancer. Gastroenterology. 2010; 139: 464-473, 473.e1-473.e3.
18. Lee PH, Shatkay H., F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 2008; 36: D820-D824.
19. Pounds S, Cheng C., Improving false discovery rate estimation. Bioinformatics. 2004; 20: 1737-1745.
20. Mathupala SP, Ko YH, Pedersen PL., Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol. 2009; 19: 17-24.
21. Mathupala SP, Rempel A, Pedersen PL., Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem. 2001; 276: 43407-43412.
22. Palmieri D, Fitzgerald D, Shreeve SM, et al. Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis. Mol Cancer Res. 2009; 7: 1438-1445.
23. Lyshchik A, Higashi T, Hara T, et al. Expression of glucose transporter-1, hexokinase-II, proliferating cell nuclear antigen and survival of patients with pancreatic cancer. Cancer Invest. 2007; 25: 154-162.
24. Green HJ, Fraser IG, Ranney DA., Male and female differences in enzyme activities of energy metabolism in vastus lateralis muscle. J Neurol Sci. 1984; 65: 323-331.
25. Matschinsky FM., Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes. 1990; 39: 647-652.
26. Sethi JK, Vidal-Puig AJ., Wnt signalling at the crossroads of nutritional regulation. Biochem J. 2008; 416: e11-e13.
27. Marshall S., Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006; 2006: re7.
28. Tong X, Zhao F, Thompson CB., The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev. 2009; 19: 32-37.
29. Niizeki H, Kobayashi M, Horiuchi I, et al. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br J Cancer. 2002; 86: 1914-1919.
30. Butkinaree C, Park K, Hart GW., O-linked beta-N-acetylglucosamine (O-GlcNAc): extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta. 2010; 1800: 96-106.